Brief: Actinium Reports 67% Response Rate In First Cohort In Actimab-A Venetoclax Combination Trial In Relapsed And Refractory AML
08/12/2020 13:29
Dec 8 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM REPORTS 67 PERCENT OVERALL RESPONSE RATE IN FIRST
COHORT IN ACTIMAB-A VENETOCLAX COMBINATION TRIAL IN RELAPSED AND
REFRACTORY AML AT ASH
* ACTINIUM PHARMACEUTICALS INC - ADDITIONAL PROOF OF CONCEPT
DATA
FROM ADVANCING COHORTS EXPECTED IN 2021
Source text for Eikon: ID:nPn7VVVqja
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities